Chemgenex patents more depression genes
Wednesday, 15 September, 2004
ChemGenex Pharmaceuticals (ASX: CXS) has filed patent applications for another five novel depression-associated gene targets, bringing the total number of gene targets with patent protection from the CNS project to 10.
The company recently signed a deal with UK group Vernalis worth AUD$2 million in the first year if milestones are achieved.
The genes, discovered by ChemGenex researchers at their Deakin University lab, were differentially expressed over a period of eight days by the Israeli sand rat when the animals were separated from their littermates. The novel animal model has been found by ChemGenex to closely mimic behavioural changes seen in human depression and anxiety.
CEO Greg Collier said the genes included several that had never been reported, and a known receptor not previously associated with depression.
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
